International application No.
PCT/JP2004/019512

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁷ C07C259/06, C07D209/22, 209/24, 211/58, 213/40, 235/16,			
295/18, 401/04, 405/04, A23L1/30, A61K7/00, 31/164, 31/165, 31/167, 31/17, 31/18, 31/275, 31/405, 31/4184, 31/4402, 31/4453,			
According to Inte	ernational Patent Classification (IPC) or to both national	, $31/405$, $31/4184$, $31/4$. al classification and IPC	402, 31/4453,
B. FIELDS SEA			
Minimum docum Int . Cl ⁷	rentation searched (classification system followed by cl C07C259/06, C07D209/22, 209/ 295/18, 401/04, 405/04, A23L	24, 211/58, 213/40, 235 1/30, A61K7/00, 31/164,	31/165,
31/4453	31/167, 31/17, 31/18, 31,		
	earched other than minimum documentation to the exte		
Electronic data b CA (STN)	ase consulted during the international search (name of a , REGISTRY (STN)	data base and, where practicable, search te	rms used)
C. DOCUMENT	TS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where ap	·	Relevant to claim No.
X A	WO 02/00593 A2 (Sigma-Tau Ir Farmaceutiche Riunite S.p.A.) 03 January, 2002 (03.01.02), & EP 1292563 A2 & JP & US 2003/195257 A1	ndustrie , 2004-501888 A	1,11-15 2-10,16-19
X A	WO 02/00261 A2 (Monsanto Technology LLC), 03 January, 2002 (03.01.02), & US 2002/068693 A1 & US 2004/171521 A1		1 2-19
X A	JP 2003-523994 A (Smithkline 12 August, 2003 (12.08.03), & WO 2001/062715 A1 & EP & US 2003/134880 A1	·	1 2-19
Further doc	uments are listed in the continuation of Box C.	See patent family annex.	
"A" document de to be of parti	cories of cited documents: Fining the general state of the art which is not considered cular relevance ation or patent but published on or after the international	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be	
filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other		 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventivate when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be 	
"O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed		considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search 01 July, 2005 (01.07.05)		Date of mailing of the international search report 19 July, 2005 (19.07.05)	
	gaddress of the ISA/ e Patent Office	Authorized officer	
Facsimile No.) (second sheet) (January 2004)	Telephone No.	

International application No.
PCT/JP2004/019512

	PCT/JP2004/019512
i). DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant	int passages Relevant to claim No.
30 August, 2001 (30.08.01),	2-19
JP 2001-500533 A (Pharmacia & Upjohn S.p 16 January, 2001 (16.01.01), & WO 99/02510 A1 & EP 925289 A1 & US 6482827 B1	.A.), 1,16-19 2-15
JP 8-81443 A (Otsuka Pharmaceutical Co., 26 March, 1996 (26.03.96), & US 5594006 A	Ltd.), 1,16-19 2-15
WO 90/09380 Al (Otsuka Pharmaceutical Co Ltd.), 23 August, 1990 (23.08.90), & EP 411150 Al & US 5238938 A	1,6-10 2-5,11-19
JP 3-74370 A (Terumo Corp.), 28 March, 1991 (28.03.91), (Family: none)	1,11-15 2-9,16-19
US 4077998 A (Morton-Norwich Products, I 07 March, 1978 (07.03.78), (Family: none)	nc.), 1 2-19
US 3950542 A (Oreal S.A.), 13 April, 1976 (13.04.76), & DE 1667903 A	1 2-19
GB 1221238 A (Merck and Co.), 03 February, 1971 (03.02.71), & DE 1816103 A & US 3639382 A	1 2-19
inhibitors of methionyl-tRNA synthetase,	2-19
by capillary electrophoresis with 18-crow tetracarboxylic acid as chiral selector,	n-6-
hydroxamates. V: Equilibrium and kinetics of the formation of the binary and ternar complexes involved in the nickel(II)-	2-19 Y
	& US 2001/046954 A1 & US 2004/171531 JP 2001-500533 A (Pharmacia & Upjohn S.p 16 January, 2001 (16.01.01), & WO 99/02510 A1 & BP 925289 A1 & US 6482827 B1 JP 8-81443 A (Otsuka Pharmaceutical Co., 26 March, 1996 (26.03.96), & US 5594006 A WO 90/09380 A1 (Otsuka Pharmaceutical Co Ltd.), 23 August, 1990 (23.08.90), & EP 411150 A1 & US 5238938 A JP 3-74370 A (Terumo Corp.), 28 March, 1991 (28.03.91), (Family: none) US 4077998 A (Morton-Norwich Products, I 07 March, 1978 (07.03.78), (Family: none) US 3950542 A (Oreal S.A.), 13 April, 1976 (13.04.76), & DE 1667903 A GB 1221238 A (Merck and Co.), 03 February, 1971 (03.02.71), & DE 1816103 A & US 3639382 A LEE, Jeewoo et al., Methionine analogs as inhibitors of methionyl-tRNA synthetase, Bioorganic & Medicinal Chemistry Letters, 1998, 8(24), 3511-3514 VERLEYSEN, Katleen et al., Enantiomeric separation of some amino acids and deriva by capillary electrophoresis with 18-crow tetracarboxylic acid as chiral selector, Journal of Microcolumn Separations, 1999, 11(1), 37-43 EL-EZABY, Mohamed S. et al., Complexes of hydroxamates. V: Equilibrium and kinetics of the formation of the binary and ternar complexes involved in the nickel(II)- histidinehydroxamic acid-pyridoxal system Journal of Inorganic Biochemistry, 1988,

International application No.
PCT/JP2004/019512

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
А	WO 2002/069965 Al (Transtech Pharma, Inc.), 12 September, 2002 (12.09.02), & US 2003/032663 Al & EP 1387680 Al & JP 2004-523565 A	

International application No.
PCT/JP2004/019512

Continuation of A. CLASSIFICATION OF SUBJECT MATTER (International Patent Classification (IPC))

Int.Cl⁷ 31/4468, 31/454, A61P1/16, 3/10, 7/02, 9/10, 13/12, 19/02, 19/08, 19/10, 25/00, 25/28, 27/10, 27/12, 29/00, 37/00, 43/00

(According to International Patent Classification (IPC) or to both national classification and IPC)

Continuation of B. FIELDS SEARCHED

Minimum documentation searched (International Patent Classification (IPC))

Int.Cl⁷ 31/4468, 31/454, A61P1/16, 3/10, 7/02, 9/10, 13/12, 19/02, 19/08, 19/10, 25/00, 25/28, 27/10, 27/12, 29/00, 37/00, 43/00

Minimum documentation searched (classification system followed by classification symbols)

A. 発明の属する分野の分類(国際特許分類(IPC))

Int.CL7 C07C259/06, C07D209/22, 209/24, 211/58, 213/40, 235/16, 295/18, 401/04, 405/04

調査を行った分野

調査を行った最小限資料(国際特許分類(IPC))

Int.CL7 C07C259/06, C07D209/22, 209/24, 211/58, 213/40, 235/16, 295/18, 401/04, 405/04

最小限資料以外の資料で調査を行った分野に含まれるもの

国際調査で使用した電子データベース(データベースの名称、調査に使用した用語)

CA (STN) REGISTRY (STN)

lc. 関連すると認められる文献

引用文献の	J C 100 9 34 0 3 X 10 X	関連する
カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	請求の範囲の番号
X	WO 02/00593 A2 (Sigma-Tau Industrie Farmaceutiche Riunite	1, 11–15
A	S.p.A.) 2002.01.03 & EP 1292563 A2 & JP 2004-501888 A & US 2003/195257 A1	2-10, 16-19
X	WO 02/00261 A2 (Monsanto Technology LLC) 2002.01.03 & US	1
A	2002/068693 A1 & US 2004/171521 A1	2-19
,		

▽ C欄の続きにも文献が列挙されている。

パテントファミリーに関する別紙を参照。

* 引用文献のカテゴリー

- 「A」特に関連のある文献ではなく、一般的技術水準を示す
 「T」国際出願日又は優先日後に公表された文献であって
- 「E」国際出願日前の出願または特許であるが、国際出願日 以後に公表されたもの
- 「L」優先権主張に疑義を提起する文献又は他の文献の発行 日若しくは他の特別な理由を確立するために引用す る文献(理由を付す)
- 「O」ロ頭による開示、使用、展示等に言及する文献
- 「P」国際出願日前で、かつ優先権の主張の基礎となる出願

の日の後に公表された文献

- 出願と矛盾するものではなく、発明の原理又は理論 の理解のために引用するもの
- 「X」特に関連のある文献であって、当該文献のみで発明 の新規性又は進歩性がないと考えられるもの
- 「Y」特に関連のある文献であって、当該文献と他の1以 上の文献との、当業者にとって自明である組合せに よって進歩性がないと考えられるもの
- 「&」同一パテントファミリー文献

国際調査報告の発送日 国際調査を完了した日 19. 7. 2005 01.07.2005 9049 特許庁審査官(権限のある職員) 国際調査機関の名称及びあて先 日本国特許庁(ISA/JP) 本堂 裕司 郵便番号100-8915 電話番号 03-3581-1101 内線 3443 東京都千代田区霞が関三丁目4番3号

C (続き).	関連すると認められる文献	関連する
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
X A	JP 2003-523994 A (スミスクライン ビーチャム パブリック リミテッド カンパニー)2003.08.12 & WO 2001/062715 A1 & EP 1265855 A1 & US 2003/134880 A1	1 2-19
X A	WO 01/62296 A2 (Monsanto Technology LLC) 2001.08.30 & US 2001/046954 A1 & US 2004/171531 A1	1 2-19
X A	JP 2001-500533 A (ファルマシア・エ・アップジョン・エッセ・ピー・アー) 2001.01.16 & WO 99/02510 A1 & EP 925289 A1 & US 6482827 B1	1, 16–19 2–15
X A	JP 8-81443 A (大塚製薬株式会社) 1996.03.26 & US 5594006 A	1, 16-19 2-15
X A	WO 90/09380 A1 (大塚製薬株式会社) 1990.08.23 & EP 411150 A1 & US 5238938 A	1, 6-10 2-5, 11-19
X A	JP 3-74370 A (テルモ株式会社) 1991.03.28 (ファミリーなし)	1, 11-15 2-9, 16-19
X A	US 4077998 A (Morton-Norwich Products, Inc.) 1978.03.07 (ファミリーなし)	1 2-19
X A	US 3950542 A (Oreal S. A.) 1976.04.13 & DE 1667903 A	1 2-19
X A	GB 1221238 A (Merck and Co.) 1971. 02. 03 & DE 1816103 A & US 3639382 A	1 2-19
X A	LEE, Jeewoo et al., Methionine analogs as inhibitors of methionyl-tRNA synthetase, Bioorganic & Medicinal Chemistry Letters, 1998, 8(24), 3511-3514	1 2-19
X A	VERLEYSEN, Katleen et al., Enantiomeric separation of some amino acids and derivatives by capillary electrophoresis with 18-crown-6-tetracarboxylic acid as chiral selector, Journal of Microcolumn Separations, 1999, 11(1), 37-43	1, 6-10 2-5, 11-19

C(続き).	関連すると認められる文献		T seek t -
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときた	は、その関連する箇所の表示	関連する 請求の範囲の番号
X A	EL-EZABY, Mohamed S. et al., Complexes of hydroxamates. V: Equilibrium and kinetics of the formation of the binary and ternary complexes involved in the nickel(II)- histidinehydroxamic acid-pyridoxal system, Journal of Inorganic Biochemistry, 1988, 33(3), 161-174		1 2-19
A	WO 2002/069965 A1 (Transtech Pharma, 2003/032663 A1 & EP 1387680 A1 & JP 2		20-24
			,
			·

- A. 発明の属する分野の分類 (国際特許分類 (IPC)) の続き A23L1/30, A61K7/00, 31/164, 31/165, 31/167, 31/17, 31/18, 31/275, 31/405, 31/4184, 31/4402, 31/4453, 31/4468, 31/454, A61P1/16, 3/10, 7/02, 9/10, 13/12, 19/02, 19/08, 19/10, 25/00, 25/28, 27/10, 27/12, 29/00, 37/00, 43/00
- B. 調査を行った分野

調査を行った最小限資料(国際特許分類(IPC))の続き A23L1/30, A61K7/00, 31/164, 31/165, 31/167, 31/17, 31/18, 31/275, 31/405, 31/4184, 31/4402, 31/4453, 31/4468, 31/454, A61P1/16, 3/10, 7/02, 9/10, 13/12, 19/02, 19/08, 19/10, 25/00, 25/28, 27/10, 27/12, 29/00, 37/00, 43/00